Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00772928 · ClinicalTrials.gov registry record · Phase 3
Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,167
- Enrollment target
NCT00772928: Completed Phase 3 study, sponsored by Sanofi.
NCT00772928 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 1,167 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (51% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00772928, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,167 participants
- Enrollment target
Study Summary
This study is designed to evaluate in a controlled manner the effect of Prevnar® on the immune responses of Pentacel™ Primary Objective - Stage I: To compare the immune responses elicited by an infant series of Pentacel™ when given at different times from or concurrently with a Pneumococcal conjugate vaccine (Prevnar®). Primary Objective - Stage II: To compare the immune responses elicited by a 4th dose of Pentacel™ when given at different times from or concurrently with Prevnar®.
Primary Outcome
Seroconversion was defined as the percentage of subjects with ≥ 4-fold post-dose 3 for anti-pertussis and ≥ 0.15 μg/mL or ≥ 1.0 μg/mL for anti-Polyribosylribitol Phosphate (PRP) responses.
Interventions
- BIOLOGICAL Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,167 participants |
| Start Date | 2003-10 |
| Est. Completion | 2006-11 |
| Phase | Phase 3 |
What the finished NCT00772928 record still lists
NCT00772928 is an interventional study that assigns participants to a tested intervention. Its 1,167 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (51% higher).
The record links to 0 conditions, and to 1 intervention - of which Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar® is the first listed.
NCT00772928 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00772928 about?
NCT00772928 is a clinical study titled "Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™". This study is designed to evaluate in a controlled manner the effect of Prevnar® on the immune responses of Pentacel™ Primary Objective - Stage I: To compare the immune responses elicited by an infant series of Pentacel™ when given at different times from or concurrently with a Pneumococcal conjug...
What is the current status of trial NCT00772928?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,167 participants. The study started on 2003-10. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00772928?
The interventions under investigation include: Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar® (BIOLOGICAL).
Who is sponsoring clinical trial NCT00772928?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00772928's enrollment target sits among peer trials
1,167 237th of 2000 higher than 1,763 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07009509 · 1,166 participants · NA
Pilot Study of the YES-CAN! Program to Prevent Youth Nicotine Vaping
- NCT06469788 · 1,170 participants · NA
Testimonials and Navigation in Rheumatology
- NCT07237048 · 1,164 participants · Phase 2
Minocycline in Stroke Study at Maimonides
- NCT04275557 · 1,174 participants
Using Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia